Table
2: Cohort study: Baseline characteristics.
|
|
Total
* |
COPD
with Depression/Anxiety |
COPD
without Depression/ Anxiety |
|||
|
Characteristic |
N |
% |
N |
% |
N |
% |
|
Number
of Patients |
31,279 |
100.00% |
12,701 |
100.00% |
18,578 |
100.00% |
|
Age
[Mean (SD)] |
77.2 |
(7.45) |
77.6 |
(7.72) |
77.0 |
(7.24) |
|
Male |
11,357 |
36.31% |
3,515 |
27.67% |
7,842 |
42.21% |
|
Region
of U.S.* |
||||||
|
Boston |
2,119 |
6.77% |
903 |
7.11% |
1,216 |
6.55% |
|
New York |
2,572 |
8.22% |
934 |
7.35% |
1,638 |
8.82% |
|
Philadelphia |
2,887 |
9.23% |
1,069 |
8.42% |
1,818 |
9.79% |
|
Atlanta |
8,587 |
27.45% |
3,873 |
30.49% |
4,714 |
25.37% |
|
Chicago |
4,634 |
14.82% |
1,776 |
13.98% |
2,858 |
15.38% |
|
Dallas |
3,772 |
12.06% |
1,545 |
12.16% |
2,227 |
11.99% |
|
Kansas City |
1,915 |
6.12% |
787 |
6.20% |
1,128 |
6.07% |
|
Denver |
826 |
2.64% |
315 |
2.48% |
511 |
2.75% |
|
San Francisco |
3,107 |
9.93% |
1,112 |
8.76% |
1,995 |
10.74% |
|
Seattle |
860 |
2.75% |
387 |
3.05% |
473 |
2.55% |
|
Race/Ethnicity |
||||||
|
White |
26,510 |
84.75% |
11,103 |
87.42% |
15,407 |
82.93% |
|
African-Americans |
2,487 |
7.95% |
753 |
5.93% |
1,734 |
9.33% |
|
Hispanic |
1,051 |
3.36% |
538 |
4.24% |
513 |
2.76% |
|
Other Races: |
1,231 |
3.94% |
307 |
2.42% |
924 |
4.97% |
|
Inpatient
Charlson Index |
||||||
|
Score = 0 |
24,127 |
77.13% |
8,960 |
70.55% |
15,167 |
81.64% |
|
Score = 1 |
3,234 |
10.34% |
1,707 |
13.44% |
1,527 |
8.22% |
|
Score ≥ 2 |
3,918 |
12.53% |
2,034 |
16.01% |
1,884 |
10.14% |
|
Outpatient
Charlson Index |
||||||
|
Score = 0 |
13,480 |
43.10% |
4,733 |
37.26% |
8,747 |
47.08% |
|
Score = 1 |
7,643 |
24.43% |
3,316 |
26.11% |
4,327 |
23.29% |
|
Score = 2 |
4,832 |
15.45% |
2,158 |
16.99% |
2,674 |
14.39% |
|
Score ≥ 3 |
5,324 |
17.02% |
2,494 |
19.64% |
2,830 |
15.23% |
|
Drugs
Pre-Index (% with any fills) |
||||||
|
Antibiotics |
15,510 |
49.59% |
6,564 |
51.68% |
8,946 |
48.15% |
|
ICS/LABA combination |
5,572 |
17.81% |
2,055 |
16.18% |
3,517 |
18.93% |
|
Inhaled cortico-steroid (ICS) |
2,048 |
6.55% |
821 |
6.46% |
1,227 |
6.60% |
|
Injected Steroids |
62 |
0.20% |
43 |
0.34% |
19 |
0.10% |
|
Ipratropium |
4,266 |
13.64% |
1,870 |
14.72% |
2,396 |
12.90% |
|
Long-acting beta-agonist (LABA) |
694 |
2.22% |
252 |
1.98% |
442 |
2.38% |
|
Leukotriene modifiers |
2,730 |
8.73% |
1,143 |
9.00% |
1,587 |
8.54% |
|
Methylxanthines |
1,187 |
3.79% |
484 |
3.81% |
703 |
3.78% |
|
Oral corticosteroids (OCS) |
6,164 |
19.71% |
2,549 |
20.07% |
3,615 |
19.46% |
|
Short-acting beta-agonist (SABA) |
6,212 |
19.86% |
2,496 |
19.65% |
3,716 |
20.00% |
|
Tiotropium |
3,767 |
12.04% |
1,280 |
10.08% |
2,487 |
13.39% |
|
any of above drugs † |
22,367 |
71.51% |
9,045 |
71.21% |
13,322 |
71.71% |
*enrollees in
non-U.S. region were not included
†use of omalizumab
and mast cell stabilizers are also included but not reported because of cell
size report restrictions